Worth reading
56In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
5
Percentage of total issued shares (%)Wording
Conditional
How definitive the wording is.Agreements reached under this partnership
Capital and Business Alliance4531Yuki Gosei Kogyo Co.,Ltd.
Alliance partner保土谷化学工業株式会社
Details of the alliance
- 1
核酸医薬品受託製造事業において協働すること
- 2
核酸医薬の原料素材からGMP製造までワンストップで対応するソリューションの提供を目指す
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
Capital and personnel relationships
This indicates whether the companies will do more than work together, such as holding each other’s shares or seconding personnel (capital and business alliance).
5.00%Our ownership stake in the partner’s shares
Number of shares acquired1,098,700株、当社発行済株式数の5％
About the partner
Business Description機能性色素、機能性樹脂、基礎化学品、アグロサイエンス製品の製造、販売等
Location東京都港区東新橋一丁目9番2号
Share capital11,196 百万円
Impact on Business Performance
本件による当社の2026年3月期通期業績への影響はございません。
| Item | Details |
|---|---|
| Name of alliance partner | 保土谷化学工業株式会社 |
| Alliance partner's business activities | 機能性色素、機能性樹脂、基礎化学品、アグロサイエンス製品の製造、販売等 |
| Alliance partner's location | 東京都港区東新橋一丁目9番2号 |
| Alliance partner's capital | 11,196 百万円 |
| Type of alliance | Capital and Business Alliance |
| Details of the alliance | 核酸医薬品受託製造事業において協働すること, 核酸医薬の原料素材からGMP製造までワンストップで対応するソリューションの提供を目指す |
| Number of shares acquired | 1,098,700株、当社発行済株式数の5％ |
| Shareholding ratio | Not disclosed → 5％ |
| Impact on Business Performance | 本件による当社の2026年3月期通期業績への影響はございません。 |
Items this document does not state (14)
Alliance partner's net salesAlliance partner's operating incomeAcquisition priceOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyDate of board resolutionContract DateAlliance start dateShare Acquisition Date and Payment DateChange in major shareholders
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.両社の強みを融合し、核酸医薬の原料素材からGMP製造までワンストップで対応するソリューションを提供するため。保土谷化学工業の原料素材開発・非GMPオリゴ核酸受託合成の機動力と製造インフラ、当社のGMP基準に準拠した製造・品質管理体制や核酸関連化合物の製造ノウハウを組み合わせるとしている。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.